Spago Nanomedical (SPAGO.ST) Stock Analysis & AI Equity Report
Spago Nanomedical (SPAGO.ST) overview
Spago Nanomedical (SPAGO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Spago Nanomedical reported revenue of SEK 0.4m and operating profit of SEK -30.9m; the year-end share price was 0.12 SEK and market capitalisation was SEK 43.7m. Spago Nanomedical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Spago Nanomedical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Spago Nanomedical
Spago Nanomedical is a Swedish clinical-stage biotechnology company developing nanomedicine-based products for cancer treatment and diagnostics. Its main programs are Tumorad, a targeted radionuclide therapy for solid tumors, and SpagoPix, a gadolinium-free MRI contrast agent designed to improve tumor imaging. The company relies on a proprietary polymeric nanoparticle platform.
Generate the Spago Nanomedical report
Spago Nanomedical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Spago Nanomedical and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.